ReviewFrontiers in aging neuroscience2020
Profiling Non-motor Symptoms in Monogenic Parkinson's Disease.
Review in Frontiers in aging neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Review
- Microglia in the crosstalk between peripheral and central nervous systems in Parkinson's disease.Translational neurodegeneration · 2025Review
- Association of Sporadic and Genetic Parkinson's Disease with Cancer: Insights from the PPMI Cohort.Genes · 2025Article
- Demographic and Clinical Profiles of Parkinson's Disease in India: Observations from a Nation-Wide Multicenter Study.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Assessing biological self-organization patterns using statistical complexity characteristics: a tool for diffusion tensor imaging analysis.Magma (New York, N.Y.) · 2025Article
- Mitochondrial Dysfunction in Genetic and Non-Genetic Parkinson's Disease.International journal of molecular sciences · 2025Review
- [Research progress on repetitive transcranial magnetic stimulation for improving depression in Parkinson's disease].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2025Review
- Non-motor symptoms of Parkinson`s disease-insights from genetics.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Dissecting Causal Links Between Gut Microbiota, Inflammatory Cytokines, and Parkinson's Disease: A Mendelian Randomization Study.Brain and behavior · 2024Article
- Precision Medicine in Parkinson's Disease: From Genetic Risk Signals to Personalized Therapy.Brain sciences · 2022Review
- α-Synuclein at the Presynaptic Axon Terminal as a Double-Edged Sword.Biomolecules · 2022Review
- Review
- The neuropsychiatry of Parkinson's disease: advances and challenges.The Lancet. Neurology · 2022Review
- New Understanding on the Pathophysiology and Treatment of Constipation in Parkinson's Disease.Frontiers in aging neuroscience · 2022Review
- Genetic architecture of Parkinson's disease subtypes - Review of the literature.Frontiers in aging neuroscience · 2022Review
- Non-Motor Symptoms and Associated Factors in Parkinson's Disease Patients in Addis Ababa, Ethiopia: A Multicenter Cross-Sectional Study.Ethiopian journal of health sciences · 2021Observational
- Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease: clues to early diagnosis and effective treatment.Archives of pharmacal research · 2021Review
- Genetic Analysis and Literature Review ofFrontiers in aging neuroscience · 2021Article
- Peripheral Clock System Abnormalities in Patients With Parkinson's Disease.Frontiers in aging neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease in the elder population, pathologically characterized by the progressive loss of dopaminergic neurons in the substantia nigra. While the precise mechanisms underlying the pathogenesis of PD remain unknown, various genetic factors have been proved to be associated with PD. To date, at least 23 loci and 19 disease-causing genes for PD have been identified. Although monogenic (often familial) cases account for less than 5% of all PD patients, exploring the phenotypes of monogenic PD can help us understand the disease pathogenesis and progression. Primary motor symptoms are important for PD diagnosis but only detectable at a relatively late stage. Despite typical motor symptoms, various non-motor symptoms (NMS) including sensory complaints, mental disorders, autonomic dysfunction, and sleep disturbances also have negative impacts on the quality of life in PD patients and pose major challenges for disease management. NMS is common in all stages of the PD course. NMS can occur long before the onset of PD motor symptoms or can present in the middle or late stage of the disease accompanied by motor symptoms. Therefore, the profiling and characterization of NMS in monogenic PD may help the diagnosis and differential diagnosis of PD, which thereby can execute early intervention to delay the disease progression. In this review, we summarize the characteristics, clinical phenotypes, especially the NMS of monogenic PD patients carrying mutations of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.